# Artiva (ARTV) — News

ARTV · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/artv/news

## Recent headlines

- [Artiva Biotherapeutics - Expects phase 3 RA trial topline results by end of 2028](https://www.ainvest.com/news/artiva-biotherapeutics-expects-phase-3-ra-trial-topline-results-2028-2609) — AInvest Wire, Sep 8, 2026
- [Artiva Biotherapeutics - To disclose updated phase 2A RA data from at least 20 patients in H2 2026](https://www.ainvest.com/news/artiva-biotherapeutics-disclose-updated-phase-2a-ra-data-20-patients-h2-2026-2609) — AInvest Wire, Sep 8, 2026
- [Artiva Biotherapeutics Inc: quarterly EPS $-0.63](https://www.ainvest.com/news/artiva-biotherapeutics-quarterly-eps-0-63-2608) — AInvest Wire, Aug 6, 2026
  Artiva Biotherapeutics Inc. (Nasdaq: ARTV) reported a quarterly earnings per share (EPS) of -$0.63 for the second quarter of 2026, slightly missing the consensus estimate of -$0.64 . The company continues to operate at a loss, consistent with its status as a pre-revenue clinical-stage biotechnology…
- [Artiva Biotherapeutics - May offer up to $400 mln in securities - SEC filing](https://www.ainvest.com/news/artiva-biotherapeutics-offer-400-mln-securities-sec-filing-2608) — AInvest Wire, Aug 6, 2026
  Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) has filed with the U.S. Securities and Exchange Commission (SEC) for a potential offering of up to $400 million in securities, according to a recent filing. The company, a clinical-stage biotechnology firm focused on developing cell therapies for…
- [Artiva Biotherapeutics announces new employee inducement grants under Nasdaq listing rule 5635(c)(4)](https://www.ainvest.com/news/artiva-biotherapeutics-announces-employee-inducement-grants-nasdaq-listing-rule-5635-4-2607) — AInvest Wire, Jul 17, 2026
  Artiva Biotherapeutics has announced the issuance of new employee inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). These grants are part of the company’s ongoing efforts to attract and retain qualified personnel, as permitted under the rule, which allows for the approval of…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).